Temozolomide

Generic Name
Temozolomide
Brand Names
Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
Drug Type
Small Molecule
Chemical Formula
C6H6N6O2
CAS Number
85622-93-1
Unique Ingredient Identifier
YF1K15M17Y
Background

Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...

Indication

Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.

Associated Conditions
Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
Associated Therapies
-
Clinical Trials
Related News

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

First Posted Date
2024-04-29
Last Posted Date
2024-06-24
Lead Sponsor
Ivy Brain Tumor Center
Target Recruit Count
450
Registration Number
NCT06388733
Locations
🇺🇸

Ivy Brain Tumor Center, Phoenix, Arizona, United States

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

First Posted Date
2024-04-03
Last Posted Date
2024-12-18
Lead Sponsor
Erasca, Inc.
Target Recruit Count
470
Registration Number
NCT06346067
Locations
🇺🇸

Texas Oncology- Austin Midtown, Austin, Texas, United States

🇺🇸

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 42 locations

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

First Posted Date
2024-02-28
Last Posted Date
2024-02-28
Lead Sponsor
Jasper Gerritsen
Target Recruit Count
464
Registration Number
NCT06283927
Locations
🇩🇪

Technical University Munich, Munich, Germany

🇳🇱

Erasmus MC, Rotterdam, Zuid-Holland, Netherlands

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM

Phase 2
Not yet recruiting
Conditions
Glioblastoma Multiforme
Interventions
Drug: Haloperidol Tablets
Drug: Temozolomide
First Posted Date
2024-01-23
Last Posted Date
2024-01-23
Lead Sponsor
Southern Medical University, China
Target Recruit Count
200
Registration Number
NCT06218524

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

First Posted Date
2024-01-11
Last Posted Date
2024-11-01
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
132
Registration Number
NCT06202066
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma

First Posted Date
2024-01-02
Last Posted Date
2024-01-02
Lead Sponsor
Zhongnan Hospital
Target Recruit Count
60
Registration Number
NCT06186440

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

First Posted Date
2023-12-15
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
478
Registration Number
NCT06172296
Locations
🇺🇸

Blank Children's Hospital, Des Moines, Iowa, United States

🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 115 locations

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

First Posted Date
2023-10-27
Last Posted Date
2023-10-31
Lead Sponsor
Beijing Pearl Biotechnology Limited Liability Company
Target Recruit Count
84
Registration Number
NCT06105619
Locations
🇨🇳

Beijing Tiantan Hospital,Capital Medical University, Beijing, Beijing, China

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients

First Posted Date
2023-10-23
Last Posted Date
2024-02-12
Lead Sponsor
Istituto Oncologico Veneto IRCCS
Target Recruit Count
36
Registration Number
NCT06095375
Locations
🇮🇹

Istituto Oncologico Veneto IRCCS, Padova, Italy

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

First Posted Date
2023-09-05
Last Posted Date
2024-08-27
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
100
Registration Number
NCT06023641
Locations
🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

🇺🇸

Sanford University, Palo Alto, California, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy